Klin Farmakol Farm. 2004;18(4):225-234

Lékové interakce antidepresiv a lithia

Michaela Procházková, Tomáš Doležal
Ústav farmakologie 3. LF UK, Praha

Keywords: drug interactions, antidepressant drugs, lithium, clinical relevance.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Procházková M, Doležal T. Lékové interakce antidepresiv a lithia. Klin Farmakol Farm. 2004;18(4):225-234.

Mezi faktory, které mohou ovlivňovat účinky léčiv, patří současné podávání jiných farmak. Způsobů, kterými spolu léky mohou vzájemně interagovat je několik, ale nejčastěji se lékové interakce dělí na farmakokinetické (absorpce, distribuce, metabolizmus, exkrece), farmakodynamické nebo na smíšené. Znalost mechanizmů, kterými nějaká interakce probíhá je důležitá v praxi, neboť při znalosti mechanizmu interakce můžeme ovlivnit její průběh nebo se jí někdy zcela záměrně můžeme vyhnout. Některé důležité interakce mezi léčivy se odehrávají na úrovni dvou či více mechanizmů.

Tabulka lékových interakcí antidepresiv a lithia je rozdělena do následujících částí: nejprve jsou uvedeny interagující léčiva, výsledek lékové interakce a její mechanizmus, klinická závažnost a dokumentace vážící se k dané interakci. Jestliže hodnotíme nějakou potenciální lékovou interakci zaměřujeme se na její klinický význam a závažnost. Potenciálně závažná léková interakce je zvláště důležitá z hlediska hodnocení risku a benefitu terapeutických možností. Při vhodné úpravě dávkování nebo úpravě režimu, můžeme řadě negativních účinků většiny interakcí předejít. V tabulce jsou uvedeny 4 stupně závažnosti interakcí, označené písmeny A-D. Úroveň dokumentace je označena čísly 1-4.

ANTIDEPRESSANT AND LITHIUM DRUG INTERACTIONS

One of the factors that can alter the response to drug is the concurrent administration of other drugs. There are several mechanisms by which drugs may interact, but most can be categorized as pharmacokinetic (absorption, distribution, metabolism, excretion), pharmacodnamic or combined interaction. Knowledge of the mechanism by which a given drug interaction occurs is often clinically useful, since the mechanism may influence both the time course and the methods of circumventing the interaction. Some important drug interactions occur as a result of two or more mechanisms.

The table of antidepressant and lithium drug interaction of antidepressant drugs and lithuim listed below is divided into the following sections: interacting drugs, outcome and mechanism of the interaction, clinical relevance and documentation of the interaction. When evaluating any potential drug ineraction, a primary concern is the clinical relevance or significance of the interaction. The potential severity of the interaction is particularly important in assessing the risk vs benefit of therapeutic alternatives. With appropriate dosage adjustments or modification of the administration schedule, the negative effects of most interactions can be avoided. In the table there are four degree of relevance of interaction and they are defined by letters A-D. Documentation levels are marked of numbers 1-4.

Download citation

References

  1. Jick H. Drugs - remarkably nontoxic. N. Engl. J Med. 1974; 291: 824-828. Go to original source... Go to PubMed...
  2. Sihvo S, Klaukka T, Martikainen J, Hemminki E. Frequency of daily over-the-counter drug use and potential clinically significant over-the-counter-prescription drug interactions in the Finnish adult population. Eur J Clin Pharmacol. 2000; 56: 495-499. Go to original source... Go to PubMed...
  3. ##
  4. Toutoungi M. Potential effect of enalapril on climipramine metabolism. Human Psychopharmacology 1992; 7: 347-349. Go to original source...
  5. Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997; 17: 118-119. Go to original source... Go to PubMed...
  6. Silverglat MJ. Baclofen and tricyclic antidepressants: possible interaction. JAMA 1981; 246: 1659. Go to original source... Go to PubMed...
  7. Burrows GD, Davies B. Antidepressants and barbiturates. Br.Med.J 1971; 4: 113. Go to original source... Go to PubMed...
  8. Garey KW, Amsden GW, Johns CA. Possible interaction between imipramine and butalbital. Pharmacotherapy 1997; 17: 1041-1042. Go to PubMed...
  9. Silverman G, Braithwaite R. Interaction of benzodiazepines with tricyclic antidepressants. Br.Med.J 1972; 4: 111. Go to original source... Go to PubMed...
  10. Abdou FA. Elavil-librium combination. Am. J Psychiatry 1964; 120: 1204. Go to original source... Go to PubMed...
  11. Beresford TP, Feinsilver DL, Hall RC. Adverse reactions to benzodiazepine-tricyclic antidepressant compound. J Clin Psychopharmacol. 1981; 1: 392-394. Go to original source... Go to PubMed...
  12. Patat A, Klein MJ, Hucher M, Granier J. Acute effects of amitriptyline on human performance and interactions with diazepam. Eur. J Clin Pharmacol. 1988; 35: 585-592. Go to original source... Go to PubMed...
  13. Gillette DW, Tannery LP. Beta blocker inhibits tricyclic metabolism. J Am. Acad. Child Adolesc. Psychiatry 1994; 33: 223-224. Go to original source... Go to PubMed...
  14. Hermann DJ, Krol TF, Dukes GE, et al. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992; 32: 176-183. Go to original source... Go to PubMed...
  15. Cotter PA. Asymptomatic tricyclic toxicity associated with diltiazem. Irish Journal of Psychological Medicine 1996; 13: 168-169. Go to original source...
  16. Krahenbuhl S, Smith-Gamble V, Hoppel CL. Pharmacokinetic interaction between diltiazem and nortriptyline. Eur. J Clin Pharmacol. 1996; 49: 417-419. Go to original source... Go to PubMed...
  17. Hillard JR, Vieweg WV. Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline. Am. J Psychiatry 1983; 140: 626-627. Go to original source... Go to PubMed...
  18. Kizer KW. Possible interaction of TCA and marijuana. Ann Emerg. Med. 1980; 9: 444. Go to original source... Go to PubMed...
  19. Wilens TE, Biederman J, Spencer TJ. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am. Acad. Child Adolesc. Psychiatry 1997; 36: 45-48. Go to original source... Go to PubMed...
  20. Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther. Drug Monit. 1993; 15: 258-260. Go to original source... Go to PubMed...
  21. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther. Drug Monit. 1994; 16: 1-12. Go to original source... Go to PubMed...
  22. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol. 1991; 11: 313-318. Go to original source... Go to PubMed...
  23. Bailey DN, Coffee JJ, Anderson B, Manoguerra AS. Interaction of tricyclic antidepressants with cholestyramine in vitro. Ther. Drug Monit. 1992; 14: 339-342. Go to original source... Go to PubMed...
  24. Geeze DS, Wise MG, Stigelman WH, Jr. Doxepin-cholestyramine interaction. Psychosomatics 1988; 29: 233-236. Go to original source... Go to PubMed...
  25. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. Ther. Drug Monit. 1994; 16: 432-434. Go to original source... Go to PubMed...
  26. Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986; 6: 8-12. Go to original source... Go to PubMed...
  27. Curry SH, DeVane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur. J Clin Pharmacol. 1985; 29: 429-433. Go to original source... Go to PubMed...
  28. Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol. Ther. 1987; 42: 278-282. Go to original source... Go to PubMed...
  29. Brion S, Orssaud E, Chevalier JF, Plas J, Waroquaux O. [Interaction between cotrimoxazole and antidepressive agents]. Encephale 1987; 13: 0123-126.
  30. Saarialho-Kere U, Julkunen H, Mattila MJ, Seppala T. Psychomotor performance of patients with rheumatoid arthritis: cross-over comparison of dextropropoxyphene, dextropropoxyphene plus amitriptyline, indomethacin, and placebo. Pharmacol. Toxicol. 1988; 63: 286-292. Go to original source... Go to PubMed...
  31. Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol. 1992; 47: M111-M115. Go to original source... Go to PubMed...
  32. Ciraulo DA, Barnhill J, Boxenbaum H. Pharmacokinetic interaction of disulfiram and antidepressants. Am. J Psychiatry 1985; 142: 1373-1374. Go to original source... Go to PubMed...
  33. Maany I, Hayashida M, Pfeffer SL, Kron RE. Possible toxic interaction between disulfiram and amitriptyline. Arch. Gen. Psychiatry 1982; 39: 743-744. Go to original source... Go to PubMed...
  34. MacCallum WA. Drug interactions in aloholism treatment. Lancet 1969; 1: 313. Go to original source... Go to PubMed...
  35. Wang JS, Wang W, Xie HG, Huang SL, Zhou HH. Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. Br. J Clin Pharmacol. 1997; 44: 195-198. Go to original source... Go to PubMed...
  36. Harding T. Fenfluramine dependence. Br. Med. J 1971; 3: 305. Go to original source... Go to PubMed...
  37. Gannon RH, Anderson ML. Fluconazole-nortriptyline drug interaction. Ann Pharmacother. 1992; 26: 1456-1457. Go to original source... Go to PubMed...
  38. Newberry DL, Bass SN, Mbanefo CO. A fluconazole/amitriptyline drug interaction in three male adults. Clin Infect. Dis 1997; 24: 270-271. Go to original source... Go to PubMed...
  39. Aranow AB, Hudson JI, Pope HG, Jr., et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am. J Psychiatry 1989; 146: 911-913. Go to original source... Go to PubMed...
  40. March JS, Moon RL, Johnston H. Fluoxetine-TCA interaction. J Am. Acad. Child Adolesc. Psychiatry 1990; 29: 985-986. Go to original source... Go to PubMed...
  41. Vandel S, Bertschy G, Bonin B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992; 25: 202-207. Go to original source... Go to PubMed...
  42. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur. J Clin Pharmacol. 1991; 40: 119-120. Go to original source... Go to PubMed...
  43. Hartter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 1993; 110: 302-308. Go to original source... Go to PubMed...
  44. Maskall DD, Lam RW. Increased plasma concentration of imipramine following augmentation with fluvoxamine. Am. J Psychiatry 1993; 150: 1566. Go to original source... Go to PubMed...
  45. Kadar D. Letter: Amitriptyline and isoproterenol: fatal drug combination. Can. Med. Assoc. J 1975; 112: 556-557.
  46. Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br. J Clin Pharmacol. 1997; 43: 315-318. Go to original source... Go to PubMed...
  47. Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone. Am. J Psychiatry 1990; 147: 1379-1380. Go to original source... Go to PubMed...
  48. Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am. J Psychiatry 1989; 146: 1611-1613. Go to original source... Go to PubMed...
  49. Cooper TB, Simpson GM. Concomitant imipramine and methylphenidate administration: a case report. Am. J Psychiatry 1973; 130: 721. Go to original source... Go to PubMed...
  50. Wharton RN, Perel JM, Dayton PG, Malitz S. A potential clinical use for methylphenidate with tricyclic antidepressants. Am. J Psychiatry 1971; 127: 1619-1625. Go to original source... Go to PubMed...
  51. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol. Ther. 1984; 35: 792-797. Go to original source... Go to PubMed...
  52. Khurana RC. Estrogen-imipramine interaction. JAMA 1972; 222: 702-703. Go to original source... Go to PubMed...
  53. Somani SM, Khurana RC. Mechanism of estrogen-imipramine interaction. JAMA 1973; 223: 560. Go to original source...
  54. Albers LJ, Reist C, Helmeste D, Vu R, Tang SW. Paroxetine shifts imipramine metabolism. Psychiatry Res. 1996; 59: 189-196. Go to original source... Go to PubMed...
  55. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997; 17: 284-291. Go to original source... Go to PubMed...
  56. Weiner AL, Tilden FF, Jr., McKay CA, Jr. Serotonin syndrome: case report and review of the literature. Conn. Med. 1997; 61: 717-721. Go to PubMed...
  57. Katz MR. Raised serum levels of desipramine with the antiarrhythmic propafenone. J Clin Psychiatry 1991; 52: 432-433.
  58. Brosen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur. J Clin Pharmacol. 1989; 37: 155-160. Go to original source... Go to PubMed...
  59. Eap CB, Laurian S, Souche A, et al. Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. Neuropsychobiology 1992; 25: 214-220. Go to original source... Go to PubMed...
  60. Pfandl B, Morike K, Winne D, Schareck W, Breyer-Pfaff U. Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica 1992; 22: 721-730. Go to original source... Go to PubMed...
  61. Bebchuk JM, Stewart DE. Drug interaction between rifampin and nortriptyline: a case report. Int. J Psychiatry Med. 1991; 21: 183-187. Go to original source... Go to PubMed...
  62. Bertschy G, Vandel S, Perault MC. [A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents]. Therapie 1994; 49: 509-512. Go to PubMed...
  63. Alderman CP, Lee PC. Comment: Serotonin syndrome associated with combined sertraline-amitriptyline treatment. Ann Pharmacother. 1996; 30: 1499-1500. Go to original source... Go to PubMed...
  64. Barros J, Asnis G. An interaction of sertraline and desipramine. Am. J Psychiatry 1993; 150: 1751. Go to original source... Go to PubMed...
  65. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol. Ther. 1997; 62: 145-156. Go to original source... Go to PubMed...
  66. Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. Br. Med. J 1973; 1: 311-315. Go to original source... Go to PubMed...
  67. Svedmyr N. The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man. Life Sci. 1968; 7: 77-84. Go to original source... Go to PubMed...
  68. Mulgirigama LD, Pare CM, Turner P, Wadsworth J, Witts DJ. Tyramine pressor responses and plasma levels during tricyclic antidepressant therapy. Postgrad. Med. J 1977; 53 Suppl 4: 30-34.
  69. Serle DG. Amitriptyline and ephedrine in subarachnoid anaesthesia. Anaesth. Intensive Care 1985; 13:214. Go to PubMed...
  70. Bowers MB, Mazure CM GMZE. Tamoxifen-associated reduction in tricyclic antidepressant levels in blood. Journal of Clinical Pharmacology 1995; 15: 223-225. Go to original source...
  71. Colantonio LA, Orson JM. Triiodothyronine thyrotoxicosis. Induction by desiccated thyroid and imipramine. Am. J Dis Child 1974; 128: 396-397. Go to original source... Go to PubMed...
  72. Extein I. Case reports of L-triiodothyronine potentiation. Am. J Psychiatry 1982; 139: 966-967. Go to original source...
  73. Prange AJ, Jr. Paroxysmal auricular tachycardia apparently resulting from combined thyroid-imipramine treatment. Am. J Psychiatry 1963; 119: 994-995. Go to original source... Go to PubMed...
  74. John VA, Luscombe DK, Kemp H. Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics of clomipramine and its desmethyl metabolite during chronic dosing. J Int. Med. Res. 1980; 8 Suppl 3: 88-95.
  75. Perel JM, Hurwic MJ, Kanzler MB. Pharmacodynamics of imipramine in depressed patients. Psychopharmacol. Bull. 1975; 11: 16-18.
  76. Perry PJ, Browne JL, Prince RA, Alexander B, Tsuang MT. Effects of smoking on nortriptyline plasma concentrations in depressed patients. Ther. Drug Monit. 1986; 8: 279-284. Go to original source... Go to PubMed...
  77. Fu C, Katzman M, Goldbloom DS. Valproate/nortriptyline interaction. J Clin Psychopharmacol. 1994; 14: 205-206. Go to original source... Go to PubMed...
  78. Granneman GR, Carlson G CJAWWSl. Modelling the extent of amitriptyline and nortriptyline metabolic inhibition during valproate coadministration. Pharmacological research 1994; 11, 10 suppl: 434.
  79. Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol. Ther. 1996; 60: 48-53. Go to original source... Go to PubMed...
  80. Benazzi F. Venlafaxine-fluoxetine-nortriptyline interaction. J Psychiatry Neurosci. 1997; 22: 278-279.
  81. Benazzi F. Anticholinergic toxic syndrome with venlafaxine-desipramine combination. Pharmacopsychiatry 1998; 31: 36-37. Go to original source... Go to PubMed...
  82. Benazzi F. Venlafaxine drug-drug interactions in clinical practice. J Psychiatry Neurosci. 1998; 23: 181-182.
  83. Saiz-Ruiz J, Moral L. Delirium induced by association of propranolol and maprotiline. J Clin Psychopharmacol. 1988; 8: 77-78. Go to original source... Go to PubMed...
  84. Tollefson G, Lesar T. Effect of propranolol on maprotiline clearance. Am. J Psychiatry 1984; 141: 148-149. Go to original source... Go to PubMed...
  85. Weddige RL. Possible trazodone-pseudoephedrine toxicity: a case report. Neurobehavioral Toxicology and Teratology 1985; 7: 204.
  86. Nawishy S, Hathway N, Turner P. Interactions of anticonvulsant drugs with mianserin and nomifensine. Lancet 1981; 2: 871-872. Go to original source... Go to PubMed...
  87. Richens A, Nawishy S, Trimble M. Antidepressant drugs, convulsions and epilepsy. Br. J Clin Pharmacol. 1983; 15 Suppl 2: 295S-298S. Go to original source... Go to PubMed...
  88. Armstrong SC, Schweitzer SM. Delirium associated with paroxetine and benztropine combination. Am. J Psychiatry 1997; 154: 581-582. Go to original source... Go to PubMed...
  89. Roth A, Akyol S, Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry 1994; 55: 492-495.
  90. Egberts AC, ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int. Clin Psychopharmacol. 1997; 12: 181-182. Go to original source... Go to PubMed...
  91. Hernandez AF, Montero MN, Pla A, Villanueva E. Fatal moclobemide overdose or death caused by serotonin syndrome? J Forensic Sci. 1995; 40: 128-130. Go to original source... Go to PubMed...
  92. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother. 1997; 31: 175-177. Go to original source... Go to PubMed...
  93. Evans M, Marwick P. Fluvoxamine and lithium: an unusual interaction. Br. J Psychiatry 1990; 156: 286. Go to original source... Go to PubMed...
  94. Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993; 26: 263-264. Go to original source... Go to PubMed...
  95. Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313-334. Go to original source... Go to PubMed...
  96. Nezelof S, Vandel P, Bonin B. Fluvoxamine interaction with fluindione: a case report. Therapie 1997; 52: 608-609. Go to PubMed...
  97. Wagner W, Vause EW. Fluvoxamine. A review of global drug-drug interaction data. Clin Pharmacokinet. 1995; 29 Suppl 1: 26-31. Go to original source... Go to PubMed...
  98. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 1993; 45: 1211-1214. Go to original source... Go to PubMed...
  99. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol. Ther. 1995; 58: 399-403. Go to original source... Go to PubMed...
  100. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions. II. J Clin Psychopharmacol. 1990; 10: 213-217. Go to original source... Go to PubMed...
  101. van Putten T, Shaffer I. Delirium associated with bupropion. J Clin Psychopharmacol. 1990; 10: 234. Go to original source... Go to PubMed...
  102. Zubieta JK, Demitrack MA. Possible bupropion precipitation of mania and a mixed affective state. J Clin Psychopharmacol. 1991; 11: 327-328. Go to original source... Go to PubMed...
  103. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 1991; 104: 323-327. Go to original source... Go to PubMed...
  104. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol. Ther. 1988; 43: 412-419. Go to original source... Go to PubMed...
  105. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J Clin Pharmacol. 1994; 38: 23-31. Go to original source... Go to PubMed...
  106. Stoll AL, Cole JO, Lukas SE. A case of mania as a result of fluoxetine-marijuana interaction. J Clin Psychiatry 1991; 52: 280-281.
  107. Christensen RC. Adverse interaction of paroxetine and cyproheptadine. J Clin Psychiatry 1995; 56: 433-434.
  108. Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 1991; 52: 163-164.
  109. Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. J Clin Psychiatry 1991; 52: 261-262.
  110. Black PN. Probable interaction between fluoxetine and itraconazole. Ann Pharmacother. 1995; 29: 1048-1049. Go to original source... Go to PubMed...
  111. Pollak PT, Sketris IS, MacKenzie SL, Hewlett TJ. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother. 1995; 29: 486-488. Go to original source... Go to PubMed...
  112. Lear J, Burden AC. Fluoxetine side-effects mimicking hypoglycaemia. Lancet 1992; 339: 1296. Go to original source... Go to PubMed...
  113. Barrett J, Meehan O, Fahy T. SSRI and sympathominetic interaction. Br. J Psychiatry 1996; 168: 253. Go to original source... Go to PubMed...
  114. Glue P, Blue P. SSRI and sympathomimetic interaction. Br. J Psychiatry 1996; 168: 653. Go to original source... Go to PubMed...
  115. Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am. J Psychiatry 1993; 150: 837. Go to original source... Go to PubMed...
  116. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222-225.
  117. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2: 850-851. Go to original source... Go to PubMed...
  118. Hansen TE, Dieter K, Keepers GA. Interaction of fluoxetine and pentazocine. Am.J Psychiatry 1990; 147: 949-950. Go to original source... Go to PubMed...
  119. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol. Psychiatry 1986; 21: 1067-1071. Go to original source... Go to PubMed...
  120. Priskorn M, Larsen F, Segonzac A, Moulin M. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur. J Clin Pharmacol. 1997; 52: 241-242. Go to original source... Go to PubMed...
  121. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993; 342: 1419. Go to original source... Go to PubMed...
  122. Soutullo CA, McElroy SL, Keck PE, Jr. Hypomania associated with mirtazapine augmentation of sertraline. J Clin Psychiatry 1998; 59: 320. Go to original source... Go to PubMed...
  123. Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm. 1993; 12: 222-225. Go to PubMed...
  124. Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother. 1994; 28: 732-735. Go to original source... Go to PubMed...
  125. Keltner N, Harris CP. Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspect. Psychiatr. Care 1994; 30: 26-31. Go to original source... Go to PubMed...
  126. Harvey AT, Burke M. Comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am. J Emerg. Med. 1995; 13: 605-607. Go to original source... Go to PubMed...
  127. Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am. J Emerg. Med. 1994; 12: 642-644. Go to original source... Go to PubMed...
  128. Askinazi C. SSRI treatment of depression with comorbid cardiac disease. Am. J Psychiatry 1996; 153: 135-136. Go to original source... Go to PubMed...
  129. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr. Scand. Suppl 1989; 350: 102-106. Go to original source... Go to PubMed...
  130. Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr. Scand. Suppl 1989; 350: 95-98. Go to original source... Go to PubMed...
  131. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol. Ther. 1997; 62: 334-347. Go to original source... Go to PubMed...
  132. Benazzi F. Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy. J Psychopharmacol. 1997; 11: 190-191. Go to original source... Go to PubMed...
  133. John L, Perreault MM, Tao T, Blew PG. Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg. Med. 1997; 29: 287-289. Go to original source... Go to PubMed...
  134. Benazzi F. Severe anticholinergic side effects with venlafaxine-fluoxetine combination. Can. J Psychiatry 1997; 42: 980-981. Go to original source... Go to PubMed...
  135. Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998; 32: 432-436. Go to original source... Go to PubMed...
  136. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol. 1996; 16: 37S-50S. Go to original source... Go to PubMed...
  137. Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry 1997; 30: 272-273. Go to original source... Go to PubMed...
  138. Heisler MA, Guidry JR, Arnecke B. Serotonin syndrome induced by administration of venlafaxine and phenelzine. Ann Pharmacother. 1996; 30: 84. Go to original source... Go to PubMed...
  139. Hodgman MJ, Martin TG, Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum. Exp. Toxicol. 1997; 16: 14-17. Go to original source... Go to PubMed...
  140. Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD. Toxic interaction of venlafaxine and isocarboxazide. Lancet 1995; 346: 1298-1299. Go to original source... Go to PubMed...
  141. Jack RA, Daniel DG. Possible interaction between pheneizine and amantadine. Arch. Gen. Psychiatry 1984; 41: 726. Go to original source... Go to PubMed...
  142. Domino EF, Sullivan TS, Luby ED. Barbiturate intoxication in a patient treated with a MAO inhibitor. Am. J Psychiatry 1962; 118: 941-943. Go to original source... Go to PubMed...
  143. Macleod I. Fatal reaction to phenelzine. Br. Med. J 1965; 5449:1554. Go to original source... Go to PubMed...
  144. Amrein R, Guntert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology (Berl) 1992; 106 Suppl: S24-S31. Go to original source... Go to PubMed...
  145. Eppel AB. Interaction between clonazepam and phenelzine. Can. J Psychiatry 1990; 35: 647. Go to original source... Go to PubMed...
  146. Macleod DM. Chorea induced by tranquillisers. Lancet 1964; 41: 388-389. Go to original source... Go to PubMed...
  147. Dillon H, Leopold RL. Acute cerebro-vascular symptoms produced by an antidepressant. Am.J Psychiatry 1965; 121: 1012-1014. Go to original source... Go to PubMed...
  148. Howarth E. Possible synergistic effects of the new thymoleptics in connection with poisoning. J Ment. Sci. 1961; 107: 100-103. Go to original source... Go to PubMed...
  149. Tordoff SG, Stubbing JF, Linter SP. Delayed excitatory reaction following interaction of cocaine and monoamine oxidase inhibitor (phenelzine). Br. J Anaesth. 1991; 66: 516-518. Go to original source... Go to PubMed...
  150. Kahn DA. Possible toxic interaction between cyproheptadine and phenelzine. Am.J Psychiatry 1987; 144: 1242-1243. Go to original source... Go to PubMed...
  151. Katz RJ, Rosenthal M. Adverse interaction of cyproheptadine with serotonergic antidepressants. J Clin Psychiatry 1994; 55: 314-315.
  152. Zubieta JK, Demitrack MA. Depression after cyproheptadine: MAO treatment. Biol. Psychiatry 1992; 31: 1177-1178. Go to original source... Go to PubMed...
  153. Rivers N HB. Possible lethal reaction between Nardil and dextromethorfan. Canadian Medical Association Journal 1970; 103: 85.
  154. Shamsie SJ, Barriga C. The hazards of use of monoamine oxidase inhibitors in disturbed adolescents. Can. Med. Assoc. J 1971; 104: 715.
  155. Garbutt JC. Potentiation of propoxyphene by phenelzine. Am. J Psychiatry 1987; 144: 251-252. Go to original source... Go to PubMed...
  156. Zornberg GL, Hegarty JD. Adverse interaction between propoxyphene and phenelzine. Am. J Psychiatry 1993; 150: 1270-1271. Go to original source... Go to PubMed...
  157. Bernstein AE. Drug interaction. Hosp. Community Psychiatry 1990; 41: 806-807. Go to original source... Go to PubMed...
  158. Stancer HC. Tardive dyskinesia not associated with neuroleptics. Am. J Psychiatry 1979; 136: 727. Go to original source... Go to PubMed...
  159. Reggev A, Vollhardt BR. Bradycardia induced by an interaction between phenelzine and beta blockers. Psychosomatics 1989; 30: 106-108. Go to original source... Go to PubMed...
  160. Berkowitz BA, Spector S, Pool W. The interaction of caffeine, theophylline and theobromine with monoamine oxidase inhibitors. Eur. J Pharmacol. 1971; 16: 315-321. Go to original source... Go to PubMed...
  161. Kline NS. Psychopharmaceuticals: effects and side effects. Bull. World Health Organ 1959; 21: 397-410. Go to PubMed...
  162. Bazire SR. Sudden death associated with switching monoamine oxidase inhibitors. Drug Intell. Clin Pharm. 1986; 20: 954-956. Go to original source... Go to PubMed...
  163. Pare CM, Al Mousawi M, Sandler M, Glover V. Attempts to attenuate the, cheese effect'. Combined drug therapy in depressive illness. J Affect. Disord. 1985; 9: 137-141. Go to original source... Go to PubMed...
  164. Barry BJ. Adverse effects of MAO inhibitors with narcotics reversed with naloxone. Anaesth. Intensive Care 1979; 7: 194.
  165. Jenkins LC, Graves HB. Potential hazards of psychoactive drugs in association with anaesthesia. Can. Anaesth. Soc. J 1965; 12: 121-128. Go to original source... Go to PubMed...
  166. Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. J Clin Psychopharmacol. 1981; 1: 319-321. Go to original source... Go to PubMed...
  167. Shee JC. Dangerous potentiation of pethidine by iproniazid, and its treatment. Br. Med. J 1960; 5197: 507-509. Go to original source... Go to PubMed...
  168. Virgan IM. Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride by pargyline hydrochloride. JAMA 1964; 187: 953-954. Go to original source... Go to PubMed...
  169. Barsa JA, Saunders JC. A comparative study of tranylcypromine and paragyline. Psychopharmacologia. 1964; 6: 295-298. Go to original source... Go to PubMed...
  170. McQueen EG. New Zealand committee on adverse drug reactions: fourteenth annual report 1979. N. Z. Med. J 1980; 91: 226-229. Go to PubMed...
  171. Elis J, Laurence DR, Mattie H, Prichard BN. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br. Med. J 1967; 2: 75-78. Go to original source... Go to PubMed...
  172. Harrison WM, McGrath PJ, Stewart JW, Quitkin F. MAOIs and hypertensive crises: the role of OTC drugs. J Clin Psychiatry 1989; 50: 64-65.
  173. Boyer WF, Lake CR. Interaction of phenelzine and sulfisoxazole. Am. J Psychiatry 1983; 140: 264-265. Go to original source... Go to PubMed...
  174. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem.Pharmacol. 1994; 47: 1253-1257. Go to original source... Go to PubMed...
  175. Horwitz D, Goldberg LI, Sjoerdsma JA. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J Lab Clin Med. 1960; 56: 747-753.
  176. Lloyd JT, Walker DR. Death after combined dexamphetamine and phenelzine. Br. Med. J 1965; 5454: 168-169. Go to original source... Go to PubMed...
  177. Simpson LL. Mechanism of the adverse interaction between monoamine oxidase inhibitors and amphetamine. J Pharmacol. Exp. Ther. 1978; 205: 392-399.
  178. Ayd FJ, Jr. Toxic somatic and psychopathologic reactions to antidepressant drugs. J Neuropsychiatr. 1961; 2(Suppl 1): 119-122. Go to original source...
  179. Ponto LB, Perry PJ, Liskow BI, Seaba HH. Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am. J Hosp. Pharm. 1977; 34: 954-961. Go to original source...
  180. Alvine G, Black DW, Tsuang D. Case of delirium secondary to phenelzine/ L-tryptophan combination. J Clin Psychiatry 1990; 51: 311.
  181. Levy AB, Bucher P, Votolato N. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment. Can. J Psychiatry 1985; 30: 434-436. Go to original source... Go to PubMed...
  182. Pope HG, Jr., Jonas JM, Hudson JI, Kafka MP. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am. J Psychiatry 1985; 142: 491-492. Go to original source... Go to PubMed...
  183. Hannah P, Glover V, Sandler M. Tyramine in wine and beer. Lancet 1988; 1: 879. Go to original source... Go to PubMed...
  184. Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D. Hypertensive episode associated with phenelzine and tap beer-a reanalysis of the role of pressor amines in beer. J Clin Psychopharmacol. 1994; 14: 5-14. Go to original source... Go to PubMed...
  185. Thakore J, Dinan TG, Kelleher M. Alcohol-free beer and the irreversible monoamine oxidase inhibitors. Int. Clin Psychopharmacol. 1992; 7: 59-60. Go to original source... Go to PubMed...
  186. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br. J Psychiatry 1967; 113: 349-365. Go to original source... Go to PubMed...
  187. Sadusk JF, Jr. The physician and the food and drug asministration. JAMA 1964; 190: 907-909. Go to original source... Go to PubMed...
  188. Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol. (Oxf) 1995; 42: 95-98. Go to original source... Go to PubMed...
  189. Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfefen JP. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol. Ther. 1991; 49: 32-38. Go to original source... Go to PubMed...
  190. Correa FJ, Eiser AR. Angiotensin-converting enzyme inhibitors and lithium toxicity. Am. J Med. 1992; 93: 108-109. Go to original source... Go to PubMed...
  191. Douste-Blazy P, Rostin M, Livarek B, Tordjman E, Montastruc JL, Galinier F. Angiotensin converting enzyme inhibitors and lithium treatment. Lancet 1986; 1: 1448. Go to original source... Go to PubMed...
  192. Pulik M, Lida H. [Interaction of lithium and angiotensin-converting enzyme inhibitors]. Presse Med. 1988; 17: 755.
  193. Sylvester RK, Leitch J, Granum C. Does acyclovir increase serum lithium levels? Pharmacotherapy 1996; 16: 466-468. Go to PubMed...
  194. Evans RL, Nelson MV, Melethil S, Townsend R, Hornstra RK, Smith RB. Evaluation of the interaction of lithium and alprazolam. J Clin Psychopharmacol. 1990; 10: 355-359. Go to original source... Go to PubMed...
  195. Koczerginski D, Kennedy SH, Swinson RP. Clonazepam and lithium - a toxic combination in the treatment of mania? Int.Clin Psychopharmacol. 1989; 4: 195-199. Go to original source... Go to PubMed...
  196. Naylor GJ, McHarg A. Profound hypothermia on combined lithium carbonate and diazepam treatment. Br. Med. J 1977; 2: 22. Go to original source... Go to PubMed...
  197. Jefferson JW. Lithium tremor and caffeine intake: two cases of drinking less and shaking more. J Clin Psychiatry 1988; 49: 72-73.
  198. Mester R, Toren P, Mizrachi I, Wolmer L, Karni N, Weizman A. Caffeine withdrawal increases lithium blood levels. Biol. Psychiatry 1995; 37: 348-350. Go to original source... Go to PubMed...
  199. Thomsen K, Schou M. Renal lithium excretion in man. Am. J Physiol 1968; 215: 823-827. Go to original source... Go to PubMed...
  200. Dubovsky SL, Franks RD, Allen S. Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry 1987; 48: 371-372.
  201. Price WA, Giannini AJ. Neurotoxicity caused by lithium-verapamil synergism. J Clin Pharmacol. 1986; 26: 717-719. Go to original source... Go to PubMed...
  202. Weinrauch LA, Belok S, D'Elia JA. Decreased serum lithium during verapamil therapy. Am. Heart J 1984; 108: 1378-1380. Go to original source... Go to PubMed...
  203. Ghose K. Interaction between lithium and carbamazepine. Br. Med. J 1980; 280: 1122. Go to original source... Go to PubMed...
  204. Shukla S, Godwin CD, Long LE, Miller MG. Lithium-carbamazepine neurotoxicity and risk factors. Am. J Psychiatry 1984; 141: 1604-1606. Go to original source... Go to PubMed...
  205. Steckler TL. Lithium- and carbamazepine-associated sinus node dysfunction: nine-year experience in a psychiatric hospital. J Clin Psychopharmacol. 1994; 14: 336-339. Go to original source... Go to PubMed...
  206. Desvilles M, Sevestre P. [Paradoxical effect of the combination of lithium and sulfamethoxazole-trimethoprim]. Nouv. Presse Med. 1982; 11: 3267-3268.
  207. Edwards IR. Medicine Adverse Reactions Committee: eighteenth annual report, 1983. N. Z. Med.J 1984; 97: 729-732. Go to PubMed...
  208. Albukrek D, Moran DS, Epstein Y. A depressed workman with heatstroke. Lancet 1996; 347: 1016. Go to original source... Go to PubMed...
  209. Muly EC, McDonald W, Steffens D, Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am. J Psychiatry 1993; 150: 1565. Go to PubMed...
  210. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am. J Psychiatry 1989; 146: 278. Go to original source... Go to PubMed...
  211. Kerry RJ, Ludlow JM, Owen G. Diuretics are dangerous with lithium. Br. Med. J 1980; 281: 371. Go to original source... Go to PubMed...
  212. Oh TE. Frusemide and lithium toxicity. Anaesth.Intensive Care 1977; 5: 60-62. Go to original source...
  213. Thornton WE, Pray BJ. Lithium intoxication: a report of two cases. Can. Psychiatr. Assoc.J 1975; 20: 281-282. Go to original source... Go to PubMed...
  214. Emilien G, Maloteaux JM. Lithium neurotoxicity at low therapeutic doses Hypotheses for causes and mechanism of action following a retrospective analysis of published case reports. Acta Neurol. Belg. 1996; 96: 281-293. Go to PubMed...
  215. Goldman SA. Lithium and neuroleptics in combination: is there enhancement of neurotoxicity leading to permanent sequelae? J Clin Pharmacol. 1996; 36: 951-962. Go to original source... Go to PubMed...
  216. Goldman SA. Lithium and neuroleptics in combination: the spectrum of neurotoxicity [corrected]. Psychopharmacol. Bull. 1996; 32: 299-309. Go to PubMed...
  217. Bocchetta A, Bernardi F, Pedditzi M, et al. Thyroid abnormalities during lithium treatment. Acta Psychiatr. Scand. 1991; 83: 193-198. Go to original source... Go to PubMed...
  218. Shopsin B, Shenkman L, Blum M, Hollander CS. Iodine and lithium-induced hypothyroidism. Documentation of synergism. Am. J Med. 1973; 55: 695-699. Go to original source... Go to PubMed...
  219. Spaulding SW, Burrow GN, Ramey JN, Donabedian RK. Effect of increased iodide intake on thyroid function in subjects on chronic lithium therapy. Acta Endocrinol. (Copenh) 1977; 84: 290-296. Go to original source... Go to PubMed...
  220. Perlman BB. Interaction between lithium salts and ispaghula husk. Lancet 1990; 335: 416. Go to original source... Go to PubMed...
  221. Hendy MS, Dove AF, Arblaster PG. Mazindol-induced lithium toxicity. Br. Med. J 1980; 280: 684-685. Go to original source... Go to PubMed...
  222. Byrd GJ. Letter: Methyldopa and lithium carbonate: suspected interaction. JAMA 1975; 233: 320. Go to original source...
  223. Yassa R. Lithium-methyldopa interaction. CMAJ. 1986; 134: 141-142. Go to PubMed...
  224. Byrd GJ. Lithium carbonate and methyldopa: apparent interaction in man. Clin Toxicol. 1977; 11: 1-4. Go to original source... Go to PubMed...
  225. Teicher MH, Altesman RI, Cole JO, Schatzberg AF. Possible nephrotoxic interaction of lithium and metronidazole. JAMA 1987; 257: 3365-3366. Go to original source...
  226. Bailey CE, Stewart JT, McElroy RA. Ibuprofen-induced lithium toxicity. South. Med. J 1989; 82: 1197. Go to original source... Go to PubMed...
  227. Kerry RJ, Owen G, Michaelson S. Possible toxic interaction between lithium and piroxicam. Lancet 1983; 1: 418-419. Go to original source... Go to PubMed...
  228. Ragheb M, Ban TA, Buchanan D, Frolich JC. Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J Clin Psychiatry 1980; 41: 397-398.
  229. Sobanski T, Bagli M, Laux G, Rao ML. Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry 1997; 30: 106-107. Go to original source... Go to PubMed...
  230. MacCallum WA. Interaction of lithium and phenytoin. Br. Med. J 1980; 280: 610-611. Go to original source... Go to PubMed...
  231. Spiers J HS. Severe lithium toxicity with normal serum concentrations. British Medical Journal 1978; 1: 185. Go to original source... Go to PubMed...
  232. Becker D. Lithium and propranolol: possible synergism? J Clin Psychiatry 1989; 50: 473.
  233. Baer L, Platman SR, Kassir S, Fieve RR. Mechanisms of renal lithium handling and their relationship to mineralocorticoids: a dissociation between sodium and lithium ions. J Psychiatr. Res. 1971; 8: 91-105. Go to original source... Go to PubMed...
  234. Hurtig HI, Dyson WL. Letter: Lithium toxicity enhanced by diuresis. N. Engl. J Med. 1974; 290: 748-749. Go to original source... Go to PubMed...
  235. Platman SR, Fieve RR. Lithium retention and excretion. The effect of sodium and fluid intake. Arch. Gen. Psychiatry 1969; 20: 285-289. Go to original source... Go to PubMed...
  236. McGennis AJ. Lithium carbonate and tetracycline interaction. Br. Med. J 1978; 1: 1183. Go to original source... Go to PubMed...
  237. Miller SC. Doxycycline-induced lithium toxicity. J Clin Psychopharmacol. 1997; 17: 54-55. Go to original source... Go to PubMed...
  238. Cook BL, Smith RE, Perry PJ, Calloway RA. Theophylline-lithium interaction. J Clin Psychiatry 1985; 46: 278-279.
  239. Perry PJ, Calloway RA, Cook BL, Smith RE. Theophylline precipitated alterations of lithium clearance. Acta Psychiatr. Scand. 1984; 69: 528-537. Go to original source... Go to PubMed...
  240. Sierles FS, Ossowski MG. Concurrent use of theophylline and lithium in a patient with chronic obstructive lung disease and bipolar disorder. Am. J Psychiatry 1982; 139: 117-118. Go to original source... Go to PubMed...
  241. Crabtree BL, Mack JE, Johnson CD, Amyx BC. Comparison of the effects of hydrochlorothiazide and furosemide on lithium disposition. Am. J Psychiatry 1991; 148: 1060-1063. Go to original source... Go to PubMed...
  242. Jefferson JW, Kalin NH. Serum lithium levels and long-term diuretic use. JAMA 1979; 241: 1134-1136. Go to original source...
  243. Poust RI, Mallinger AG, Mallinger J, Himmelhoch JM, Neil JF, Hanin I. Effect of chlorothiazide on the pharmacokinetics of lithium in plasma and erythrocytes. Psychopharmacol. Commun. 1976; 2: 273-284. Go to PubMed...
  244. Fava S, Galizia AC. Neuroleptic malignant syndrome and lithium carbonate. J Psychiatry Neurosci. 1995; 20: 305-306.
  245. Kojima H, Terao T, Yoshimura R. Serotonin syndrome during clomipramine and lithium treatment. Am. J Psychiatry 1993; 150: 1897. Go to original source... Go to PubMed...
  246. Rosenberg PB, Pearlman CA. NMS-Like syndrome with a lithium/doxepin combination. J Clin Psychopharmacol. 1991; 11: 75-76. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.